Instalab
logoInstalab

Can I Stop Taking Statins After Age 70?

Stopping a statin after 70 is an option, but the new evidence favors keeping it if the pill isn't bothering you and prevention remains your priority. In a new randomized trial of older adults with several chronic conditions and no known cardiovascular disease, more people assigned to stop had a heart attack, stroke, or died. Stopping didn't show a substantial benefit in how they felt either. When serious illness shortens the time ahead, stopping becomes a reasonable choice to make with your physician.

Can I Stop Taking Statins After Age 70?

If you've taken a statin for years and you're now in your seventies, it's fair to wonder whether the pill is still doing anything for you. Until recently, that question leaned heavily on observational studies, which linked stopping to more cardiovascular events but couldn't rule out that the people who stopped were sicker or frailer to begin with. STREAM, a randomized trial presented at the American Heart Association's Scientific Sessions in November 2026 and published in the New England Journal of Medicine, assigned long-term statin users to stop or continue their statin and any other LDL-lowering treatment. It met its statistical goal, so it's being reported as showing that stopping was noninferior. But fewer people assigned to continue had a heart attack, stroke, or died, and stopping didn't show a substantial improvement in how participants felt.

What the trial allowed itself to lose

STREAM enrolled 1,880 adults aged 70 or older, average age 77.5, at sites in Switzerland, the Netherlands, and France. Each had at least two chronic conditions and no known cardiovascular disease, and had been taking a statin to prevent a first heart attack or stroke for at least a year. That makes it a trial about whether to stop a drug you already take, which is a different question from whether to start one.

The main outcome bundled nonfatal heart attack, nonfatal ischemic stroke, and death from any cause, and measured it as event-free time: out of the first two years, how many weeks the average participant spent alive and free of a heart attack or stroke. The investigators and an advisory board agreed in advance that losing up to 5.2 weeks over two years would be acceptable in this population. The estimated loss and its uncertainty range stayed inside that limit, so stopping passed. The loss itself wasn't zero, though, and the reported uncertainty range favored continuation throughout. Most participants had no event at all; for someone who has a stroke after stopping, the cost is the stroke and whatever it takes from the years after it.

Counting the extra serious events

The event counts make the tradeoff easier to see. During the trial, about 12.7% of people assigned to stop had a nonfatal heart attack or ischemic stroke or died, compared with about 9.2% of those assigned to continue. That's roughly 3 or 4 more people out of every 100. These are crude proportions across the whole follow-up, so they can't be read as a two-year risk. Because the groups were randomly assigned, this is stronger evidence about the effects of a stopping strategy than the earlier observational studies could give.

If you're weighing this for yourself, 3 or 4 per 100 describes the difference between the two trial groups as a whole. Most participants who stopped had no event during follow-up, but these outcomes are serious and often permanent, and the trial hasn't shown a reliable way to tell in advance who would have an event.

The biology fits. In a subsample checked after a year, LDL in the group that stopped was far above the group that continued. That's the expected effect of taking away a statin, though the measurement alone doesn't show that the cholesterol rebound caused the extra events.

STREAM also adds to an earlier randomized result. The French SAGA/SITE trial, in adults 75 and older, found stopping noninferior for death from any cause over three years. STREAM's outcome also counted nonfatal heart attacks and strokes, the events a statin is meant to prevent, which is part of why the two trials can read differently.

A few features limit how precisely the numbers can be read. The trial was open-label, so participants knew whether they were still taking a statin, though heart attacks and strokes were judged by reviewers who didn't know group assignment. A sizable number of people in each group switched strategies during the trial; the investigators reported an analysis suggesting this didn't change the conclusion, which can't be checked until the full paper is accessible.

No demonstrated payoff in comfort

The case for stopping can rest on feeling better: fewer aches, one fewer pill, less worry about side effects. STREAM measured symptoms and quality of life directly, and the reported results showed no substantial differences between the groups in quality of life, pain, falls, or risk of age-related muscle loss. Every participant had already taken a statin for at least a year, so these findings describe established users.

When stopping can still be the right call

None of this makes stopping wrong for everyone. Guidance on older adults from the American Heart Association, written before STREAM, says the decision should weigh your priorities, function, frailty, number of medications, and life expectancy, says age alone shouldn't decide it, and notes that stopping may be reasonable when life expectancy is under a year. That judgment turns on prognosis and personal goals, and it's a conversation to have with the physician who manages your medications.

The results also have limits on who they cover. They come from people already on a statin, so they don't settle whether to start one after 70, and they don't directly apply to people who have had a heart attack or stroke, or to generally healthy older adults with few other conditions.

The full journal article wasn't accessible when this was checked. Its indexed abstract confirms the main event and serious-adverse-event results, while some details, including LDL, quality of life, and switching, still rely on conference coverage. Reviewing the analyses that account for switching, along with longer follow-up, would help clarify the size and durability of the gap, and prespecified, replicated analyses showing that some group of older adults can stop without extra heart attacks, strokes, or deaths, or that stopping helps them feel or function better, would make stopping an easier choice for those people. For now, if your statin isn't bothering you and preventing a heart attack or stroke still matters to you, STREAM gives you a concrete reason to keep taking it.

Not sure where to start?

Answer a few questions about your health and we'll build you a Game Plan: the tests and screenings worth getting, plus the medications, supplements and lifestyle changes that could help.

2-min assessment · No commitment · HIPAA-compliant